Nalagenetics Pte. Ltd. has landed $12.6 million in a series A round of financing. The Singapore-based company wants to use the capital to expand on its genetic testing solutions to implement predictive and presymptomatic testing for prevention geared towards chronic conditions in Asia.

Shouyao Holdings Co. Ltd. raised ¥1.48 billion ($233 million) in a listing on the Shanghai STAR Market to support the company’s ongoing clinical programs, led by a second-generation anaplastic lymphoma kinase inhibitor. Company shares (SHA:688197) debuted at ¥39.90, then fell 19.5% to close at ¥32.11 on March 23.

U.K. health tech startup Sano Genetics Ltd. landed $11 million to develop a genetic data-sharing platform that connects patients with clinical researchers. MMC Ventures led the series A funding round, with Episode 1, Seedcamp and other individual investors participating.

AN2 Therapeutics Inc., a company developing a once-daily treatment for people with chronic non-tuberculous mycobacterial lung disease, raised $69 million in an upsized IPO. The offering of 4.6 million shares (NASDAQ:ANTX), initially priced at $15 each, met a modest market reception, with shares rising to $15.40 by market close on March 25. The Menlo Park, Calif.-based company is developing epetraborole, a boron-containing small-molecule inhibitor of bacterial leucyl-tRNA synthetase, in-licensed from Anacor Pharmaceuticals Inc., now part of Pfizer Inc.